Canterbury DHB


Treatment of AP and BP CML

Choice of treatment of chronic myeloid leukaemia in accelerated and blast crisis should be made by the treating specialist in light of:

Treatment within a clinical trial is preferable.

For previously untreated patients, the 2013 European LeukemiaNet guidelines5 recommend:

Consider alloSCT for fit patients with a high risk for transformation, since the outcome of alloSCT after transformation is unfavourable. Also consider alloSCT early in patients developing AP on a TKI, or high-risk patients with insufficient treatment response.

The only curative option for patients in BP disease is alloSCT. However, for patients considered high risk alloSCT candidates, on-going drug treatment or best supportive care might be the better option.

About this Canterbury DHB document (533105):

Document Owner:

Bridgett McDiarmid (see Who's Who)

Last Reviewed:

August 2018

Next Review:

April 2021


Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 533105